Search Results - martin+prlic

2 Results

Sort By:

MAIT CTLA4

MAIT Cell Immunomodulation for Targeted Treatment of Inflammatory Diseases MAIT cells undergo targeted therapeutic exploitation to alter CTLA-4 expression and dampen inflammatory responses. Mucosal-associated invariant T (MAIT) cells are non-conventional T cells that localize within inflamed tissue. Upon activation, MAIT cells act as...

Published: 12/27/2023 | Updated: 10/22/2019 | Inventor(s): Martin Prlic, Julia Berkson, Chloe Slichter

Keywords(s): Assay / Method

Category(s): Cell Therapy

Multimeric NKG2D for immunomodulation

NKG2D Biologic to Reduce Immune Cell Activation A multimeric decoy to block activation of NKG2D and treat autoimmune and inflammatory diseases, and for use in vaccine development. Dr. Roland Strong and Dr. Martin Prlic have developed a multimeric NKG2D decoy that will bind all NKG2D ligands and block the NKG2D pathway. NKG2D is a receptor...

Published: 12/27/2023 | Updated: 10/21/2019 | Inventor(s): Roland Strong, Martin Prlic, Mesfin Gewe, Thomas Spies, Veronika Groh-Spies, Peter Rupert

Keywords(s): Protein / Peptide

Category(s): Therapeutic, Vaccine